The vasoconstrictor drugs in the treatment of the Hepatorenal syndrome.The randomized clinic end multicentric study. - (HRS) study

• Conditions: HRS Syndrome; MedDRA version: 6.1Level: PTClassification code 10019845

• Registration Number: EUCTR2006-005014-13-IT
• Lead Sponsor: AZIENDA OSPEDALIERA DI PADOVA

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2007-06-05
• Last Update Posted: 19 March 2012

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

cirrotic patients age 18-75

Diagnosis of HRS type 1 or2 with plasmatic creatinin superior to 2,5 mg/dl
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

-hepatic K ,batteric infection with septic shock.Respiratory and heart failure.Presence of periferic arteriopaty.ischemic cardiomiopaty

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: valutation the efficacy and safety two treatment in the hepatorenal syndrome;Secondary Objective: -survival at 1 and 3 mounth<br><br>-liver failure<br><br>-liver function<br><br>-PAO and FC<br><br>-vasocostrictor parameters.;Primary end point(s): total recovery of renal function.